The Importance of Funding Early Innovation. Roel Bulthuis, Head of MS Ventures.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The Importance of Funding Early Innovation. Roel Bulthuis, Head of MS Ventures.
Released on: July 08, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.
  • Summary
  • Transcript
  • Participants
  • Company
MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. They invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes. Along with the €100 million MS Ventures fund, their team also manages the €30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs and the € 10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel. Roel Bulthuis, Head of MS Ventures, Merck Serono Ventures updates Fintan Walton on their latest successes.
MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA. They invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes. Along with the €100 million MS Ventures fund, their team also manages the €30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs and the € 10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel. During the Anglonordic Lifesciences Conference Roel Bulthuis, Head of MS Ventures updated Fintan Walton on their latest successes.
Roel Bulthuis
MS Ventures
Merck Serono
Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Geneva, Switzerland.[1] In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. As of January 5, 2007, Merck held the majority shares of Serono. The new company is called Merck Serono International S.A.